8-K: Galectin Therapeutics Reports Positive Belapectin Results in U.S. MASH Cirrhosis Patients

Galectin Therapeutics announces a significant reduction in new varices with belapectin in U.S. patients from the NAVIGATE trial, indicating potential for treating MASH cirrhosis.

Summary

• Galectin Therapeutics announced additional results from the NAVIGATE trial, focusing on U.S. patients with MASH cirrhosis and portal hypertension.
• The analysis showed a statistically significant 68.1% reduction (p=0.02) in the incidence of new varices in per-protocol patients (completers) treated with belapectin compared to placebo.
• This result was observed in the U.S. cohort of the completer population (n=186), where 4 out of 60 patients on belapectin developed new varices compared to 13 out of 62 on placebo.
• The company estimates that around 3 million adults in the U.S. suffer from MASH cirrhosis and clinically significant portal hypertension.
• Full analysis of the NAVIGATE trial is ongoing, with additional data expected by the end of Q1 2025.
• The company plans to determine next steps for belapectin development with potential partners.

Sentiment

Score: 7

Explanation: The document presents positive clinical data, but also acknowledges the need for partnerships and further development, resulting in a moderately positive sentiment.

Positives

• The 68.1% reduction in new varices in U.S. patients is a statistically significant and positive outcome for belapectin.
• The results suggest belapectin's potential as a treatment for MASH cirrhosis and portal hypertension.
• The company is continuing to analyze the data and plans to determine next steps with potential partners.
• The company expects to share additional clinical updates as data becomes available in the first quarter of 2025.

Negatives

• The NAVIGATE trial's top-line results did not reach statistical significance in the intent-to-treat population (N=355).
• Advancement of additional clinical programs is largely dependent on finding a suitable partner.

Risks

• Trial endpoints required by the FDA may not be achieved.
• Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development.
• The Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters.
• The Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly.
• Plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies.
• Regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials.
• Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations.

Future Outlook

The company anticipates sharing additional clinical updates as data becomes available in the first quarter of 2025 and will determine next steps for belapectin development with potential partners.

Management Comments

• Joel Lewis, Chief Executive Officer at Galectin Therapeutics, commented: 'With the prevalence of MASH cirrhosis and clinically significant portal hypertension in the U.S. now estimated in Hepatology at around 3 million adults, the need for new treatments that can prevent disease progression is more urgent than we had anticipated.'
• Joel Lewis, Chief Executive Officer at Galectin Therapeutics, commented: 'The significant reduction of 68% we see in incidence of new varices in completer patients in the U.S. from the NAVIGATE trial underscores belapectin's potential as a treatment for MASH cirrhosis and portal hypertension.'

Industry Context

The announcement addresses the urgent need for new treatments for MASH cirrhosis and portal hypertension, a significant and growing medical problem in the U.S. with an estimated 3 million adults affected. The positive results for belapectin could position Galectin Therapeutics as a leader in this therapeutic area.

Comparison to Industry Standards

• Currently, there are no FDA-approved therapies for MASH cirrhosis and clinically significant portal hypertension, making belapectin a potential first-in-class treatment if approved.
• The 68.1% reduction in new varices observed in the U.S. patient population represents a significant improvement compared to existing treatment options, which primarily focus on managing complications rather than preventing disease progression.
• Companies like Intercept Pharmaceuticals and CymaBay Therapeutics are also developing treatments for NASH/MASH, but Galectin's focus on belapectin's mechanism of action (galectin-3 inhibition) differentiates it from some competitors.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of belapectin could improve the lives of patients with MASH cirrhosis and portal hypertension.
• Potential partnerships could provide financial stability and resources for further development.

Next Steps

• The company will continue to analyze data from the NAVIGATE trial, including 36-month treatment data.
• The company will determine next steps for belapectin development with potential partners.

Key Dates

Keywords

belapectin, Galectin Therapeutics, MASH cirrhosis, portal hypertension, NAVIGATE trial, varices, liver disease, clinical trial